DB04: TDxd vs TPC in HER2-low mBC

✅~5m increase in PFS
✅~6m improvement in OS (wow!)
✅Benefit seen in HR+ &TNBC cohorts
✅ Safety consistent & manageable
❗️ILD/pneumonitis mostly grade 1/2 although 3 associated deaths seen

📣Practice changing results!

#ASCO22 OncoAlert

DB03: Safety update

✅No new safety signals with TDxd
✅No additional grade 3 ILD events
✅Most TRAEs were grade 1/2

❗️Note that risks of N/V, fatigue and alopecia were higher with TDxd, particularly in initial cycles

#ASCO2022 OncoAlert #bcsm

Abstract 1020: Exploratory biomarker analysis of DestinyBreast04

✅ TDxd was superior to TPC in all subgroups including different intrinsic subtypes, ESR1, PIK3CA!

#bcsm Oncology Brothers OncoAlert

Relevant update on T-DXd-related ILD presented at #AACR21

Analysis on 879 pts from 8 TDXd trials (58% BC)

👉15.8% experienced ILD, w/ 21 fatal cases (2.4%)
👉median T to onset 5.5 months
🚨paramount to develop effective preventing & treatment strategies

onclive.com/view/trastuzum…

In breast oncology there is a pre-TDXd & a post-TDXd era, with the latter still at the dawn. What makes a tumor resistant to T-DXd? How to treat such tumor? This open access ESMO Open article by Gabriele Antonarelli reviews the management of HER2+ MBC beyond T-DXd. esmoopen.com/article/S2059-…

🇮🇹 Italian real-world data of T-DXd in patients with HER2+ metastatic breast cancer: The DE-REAL Study

✅ Efficacy and safety of T-DXd were confirmed and in line with DB01, DB02, and DB03.

🇮🇹 definitely 👍 (and not 👎 or 🤌)

academic.oup.com/oncolo/advance…

#ADCs #TDXd #RWD

In response to #Tdxd activity in breast cancer across almost all IHC levels, a better, more quantitative scoring system for HER2 is urgently needed. #bcms #onctwitter #her2

HER2 IHC testing is now a must on all metastatic solid tumors. New opportunity for thousands of patients! #ADC #Tdxd #MedTwitter OncoAlert U.S. FDA ASCO

7 new drugs/indications were approved by FDA Oncology for lung cancer in 2022:

- #Nivolumab in neoadj
- #Capmatinib
- #TDxD
- #Selpercatinib
- #Adagrasib
- More IO options

Here is a summary table:

#MedTwitter OncoAlert #OncTwitter #LCSM IASLC #lungcancer #OncEd #MedEd

DAR To SHZ
📍 Igumbilo

01. Sauli T668DTF 13:28
02. Golden T712DPK 13:29
03. Imani + TDXD 13:29

Cancer Network's (CancerNetwork®) top 5 articles of the week

oncodaily.com/49946.html

#oncodaily #oncology #cancer #FDA #acceleratedapproval #TDXd #HER2 + #solidtumors #ASCO #vaccine #CDK9inhibitor #AML #microbiome #rectalcancer #ideCel #multiplemyeloma #cancer treatment

BREAKING NEWS for Her2+ #MBC w/ #brainmets : TDXd resulted in intracranial response rate of 64% vs. 33% w/TDM1, and 28% had COMPLETE RESPONSE IN THE BRAIN, DESTINY-Breast03 by Dr. Sara Hurvitz #sabcs21 #her2 #bcsm #chemo SABCS

.Sara Tolaney discusses #SABCS21 highlights for HER2+ BC & I'm so excited to see that Enhertu (TDxD) has such high objective response rates in pts with #brainmets & even in pts w/ a HER2 IHC of 0! The James The Ohio State University Wexner Medical Center #BCSM

First up TDXd aka Enhertu, a ADC approved for both HER2+ and HER2low MBC. Pretty sure it was approved in HER2low population about a year ago due to results from DESTINY-breast02 trial. #SABCS23

Game changed!!! Amazing data from DestinyB04 in favor of TDXd for HER2 low #mbc #ASCO22 #bcsm

Important study: DESTINY-Breast09 looking at TDXd +/- pertuzumab vs THP for 1L therapy of HER2+ MBC; currently enrolling

DESTINY CRC-01 ph2 update: n=86, TDXd in refractory HER2+ mCRC (2-3%)
ORR 45% in IHC3+, IHC2+/ISH+, impressive mOS 15.5mos ✅
No benefit in IHC2+/ISH-, IHC1+
ILD risk 9% (3% fatal)⛔️
#ASCO21 #CRCSM

Impressive data on TDxD improving PFS and OS in HER2-low breast cancer + standing ovation at #ASCO22 with deafening applause!
No responses in HER2-low mCRC in DESTINY-CRC01. Why? Thoughts? Sara Lonardi Chiara Cremolini Jenny Seligmann Filippo Pietrantonio Pashtoon Kasi MD, MS Ben Westphalen

3 new drugs/indications were approved by FDA Oncology for Breast Cancer and 2 for Gyn Onc in 2022. Here is a summary!

- #TDXd x 2
- #Olaparib
- #Pembrolizumab
- #Mirvetuximab

#bcsm #gynsm OncoAlert #breastcancer #MedTwitter #OncEd #MedEd #ovariancancer

Goosebumps & standing ovations for #her2 low #mbc #breastcancer with #tdxd Clear clinically meaningful & stat sig improvements with the ADC vs Inv choice chemo. OS & PFS benefit irrespective of #hormonepositive or #tnbc status #asco22 OncoAlert #bcsm